AI use case

AI for Respiratory Drug Discovery

Exscientia, an Oxford-based AI drug discovery company, applied its AI-driven platform to respiratory disease drug discovery. The company's automated systems and machine learning…

Browse catalog

At a glance

Core facts from this catalog record. Primary narrative lives in the hero above; full raw fields follow in the next section.

Company/Organization: AstraZeneca
Industry: Pharmaceuticals
Location: Oxford

Record fields

Every column from the source row, in stable order. URLs open in a new tab.

Title

AI for Respiratory Drug Discovery

Content

Exscientia, an Oxford-based AI drug discovery company, applied its AI-driven platform to respiratory disease drug discovery. The company's automated systems and machine learning algorithms enabled rapid identification of optimized compounds for respiratory conditions. Exscientia's approach combined phenotypic screening with AI-driven design to generate novel compounds addressing unmet medical needs in respiratory diseases. The AI platform continuously learned from experimental data to improve compound predictions. In 2021, Exscientia announced a collaboration using their AI platform for virus protease inhibitor design, demonstrating broad applicability across respiratory and infectious diseases. Note: Exscientia merged with Recursion in 2024.

URL

https://www.sumitomo-pharma.com/news/20200130.html

Continue exploring AI deployments in the catalog.

Back to use cases